FIELD: medicine.
SUBSTANCE: group of inventions relates to glycemic control in diabetes type 2 patients with glucose concentration 2 hours after meal at least 14 mmol/l, glycaemia in whom is not controlled properly only by basal insulin. There are disclosed: a pharmaceutical combination for use at the specified purpose, containing lixisenatide (AVE0010, desPro36Exendin-4(1-39)-Lys6-NH2 and/or its pharmaceutically acceptable salt), basal insulin or pharmaceutically acceptable salt thereof, and a corresponding method for improving glycemic control; combination and method can optionally include metformin or its salt.
EFFECT: technical result consists in implementing the declared application and significant reduction of HbA1c glycated hemoglobin.
17 cl, 35 tbl, 13 dwg
